

**DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health  
National Cancer Institute  
Bethesda, Maryland**

**AGENDA**

**66<sup>th</sup> Meeting  
of the  
NCI Council of Research Advocates (NCRA)**

**October 21, 2014**

**Tuesday, October 21 - OPEN  
Conference Room 6, C Wing, Building 31**

**9:00 a.m. – 9:20 a.m.**

**I. CALL TO ORDER AND OPENING REMARKS**

Mr. Wallace  
Ms. Landy

**II. FUTURE MEETING DATES**

**NCRA Confirmed:**

February 5, 2015

Thursday

June 22, 2015

Monday

October 19, 2015

Monday

**9:20 a.m. - 9:50 a.m.**

**III. THE ROLE OF ADOPTIVE T-CELL THERAPY**

Dr. Rosenberg

**9:50 a.m. - 10:20 a.m.**

**IV. IMMUNOTHERAPIES IN CHILDHOOD CANCER**

Dr. Mackall

**10:20 a.m. - 10:50 a.m.**

**V. THERAPEUTIC CANCER VACCINES**

Dr. Schlom

**10:50 a.m. - 11:20 a.m.**

**VI. CANCER IMMUNOPREVENTION EFFORTS**

Dr. Schiller

**11:20 a.m. – 11:30 a.m.**

**COFFEE BREAK**

**11:30 a.m. – 12:00 p.m.**

VII. NCI DIRECTOR'S UPDATE

Dr. Varmus

**12:00 p.m. – 1:00 p.m.**

LUNCH

**1:00 p.m. – 1:30 p.m.**

VIII. REGULATORY ADVANCES IN CANCER IMMUNOTHERAPIES

Dr. Bross

**1:30 p.m. – 2:00 p.m.**

IX. PARTNERING WITH THE PRIVATE SECTOR TO ADVANCE  
CANCER IMMUNOTHERAPIES

Ms. Selig

**2:00 p.m. – 2:40 p.m.**

X. FACILITATED DISCUSSION: HOW ADVOCATES CAN ADVANCE  
CANCER IMMUNOTHERAPY RESEARCH

**2:40 p.m. – 3:10 p.m.**

XI. WORKING GROUP UPDATES

Ms. Harris  
Mr. Retzlaff  
Mr. Wallace

**3:10 p.m. – 3:30 p.m.**

XII. OPEN DISCUSSION

**3:30 p.m.**

XIII. ADJOURNMENT

## **SPEAKERS**

**Peter Bross, M.D.**  
**Medical Review Officer**  
**Office of Cellular, Tissue, and Gene Therapies**  
**Center for Biologics Evaluation and Research**  
**Food and Drug Administration**  
**Silver Spring, MD**

**Joya Delgado Harris, M.P.H.**  
**Director**  
**Office of Research Integration**  
**American Cancer Society**  
**Atlanta, GA**

**Kelley Landy, M.P.A.**  
**Acting Director**  
**Office of Advocacy Relations**  
**Office of the Director**  
**National Cancer Institute**  
**National Institutes of Health**  
**Bethesda, MD**

**Crystal Mackall, M.D.**  
**Chief, Pediatric Oncology Branch**  
**Head, Immunology Section**  
**Center for Cancer Research**  
**National Cancer Institute**  
**National Institutes of Health**  
**Bethesda, MD**

**Jon Retzlaff, M.P.A., M.B.A.**  
**Managing Director**  
**Science Policy and Government Affairs**  
**American Association for Cancer Research**  
**Washington, DC**

**Steven A. Rosenberg, M.D., Ph.D.**  
**Chief, Surgery Branch**  
**Head, Tumor Immunology Section**  
**Center for Cancer Research**  
**National Cancer Institute**  
**National Institutes of Health**  
**Bethesda, MD**

**John T. Schiller, Ph.D.**  
**Deputy Chief, Laboratory of Cellular Oncology**  
**Head, Neoplastic Disease Section**  
**Center for Cancer Research**  
**National Cancer Institute**  
**National Institutes of Health**  
**Bethesda, MD**

**Jeffrey Schlom, Ph.D.**  
**Chief, Laboratory of Tumor Immunology and Biology**  
**Head, Immunotherapeutics Group**  
**Center for Cancer Research**  
**National Cancer Institute**  
**National Institutes of Health**  
**Bethesda, MD**

**Wendy K.D. Selig**  
**President and Chief Executive Officer**  
**Melanoma Research Alliance (MRA)**  
**Washington, DC**

**Harold E. Varmus, M.D.**  
**Director**  
**National Cancer Institute**  
**National Institutes of Health**  
**Bethesda, MD**

**Max Wallace, J.D.**  
**Chief Executive Officer**  
**Accelerate Brain Cancer Cure**  
**Washington, DC**